

In a few years “microbiota-friendly” has gone from a niche concept to a mass claim. The concept is sound; the problem is that very different dossiers sit behind the same word, some with data and some with an intention. The useful question, for anyone formulating, is what you need to have measured before that claim holds up in front of a customer, a distributor and, when required, an authority.
The most common misunderstanding is to read microbiota-friendly as the absence of antimicrobial activity. It is not: a preservative has to preserve and an anti-acne active has to act. What is being claimed is selectivity — inhibiting the unwanted microorganisms while leaving room for the resident ones that keep the ecosystem in balance. Experimentally that means something precise: a minimum inhibitory concentration on the pathogen is not enough. You need at least two columns in the same table, target and commensal, measured under the same conditions and on the same matrix.
Antimicrobial selectivity. A direct comparison between the effect on unwanted microorganisms and the effect on resident ones. This is the datum that carries the claim: without it, “respects the microbiota” remains a statement.
Prebiotic activity. The complement: not only no damage, but active support for the growth of the desired species. It is measured on selected cultures and, where it makes sense, on consortia that come closer to the reality of the site.
3D models and adhesion. On reconstructed skin tissue behaviour changes compared with a plate: there is a barrier, a structure, competition for adhesion. This is the step that brings the data closer to real use conditions.
Downstream effects. A microbial balance that shifts has measurable consequences on the tissue: inflammatory cytokine production, barrier integrity. These are the endpoints that turn a microbiological result into a cosmetic benefit you can talk about.
In the strains you choose. A commensal from a collection, grown in comfortable conditions, does not represent the population that actually lives on that site. Panel selection is half the result, and it has to be justified in the dossier, not merely performed.
In the matrix. The pure active and the finished formula behave differently: surfactants, preservatives and pH can erase the selectivity observed on the ingredient. If the claim is on the product, the data have to be generated on the product.
In the site. Skin, oral cavity and intimate area have different ecosystems, different pH and different reference species. Data from one do not transfer to the others, however tempting that is for communication.
Less than people fear, if the design is focused: a selectivity package on a well-reasoned panel plus prebiotic activity closes in a few weeks. What inflates time and cost is the wrong order: starting from 3D models before establishing whether selectivity exists means spending on the expensive part of an unverified hypothesis.
Is the claim on the ingredient or on the finished product? What you test depends on this, and it is not a formality. Which site, and with which panel of microorganisms? That is the choice to defend first. And who will be shown the dossier: a formulator, a regulatory office and a buyer ask for different depth.
In the cosmetics division microbiological tests are designed together with the claim, not afterwards: we start from how the sentence will read on the label and work backwards to the minimum evidence package that supports it. The strain panel is chosen for the site, selectivity is verified on the real matrix, and 3D models are added when there is already something to confirm. It is a way of working that tends to produce fewer data, and more usable ones.
The page on antimicrobial effect and microbiota describes the available assays and endpoints; the page on ingredient testing frames the full path, from early screening to claim substantiation. If the claim is still open, that is where to start.
Technical content and news from our laboratories, sent when there is something worth saying.